慢性淋巴细胞白血病相关免疫性血小板减少的病理机制及治疗进展  

Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia:Pathological Mechanism and Treatment Progress——Review

作　　者：黄梦贞 王诗轩 李菲[1,2,3] HUANG Meng-Zhen;WANG Shi-Xuan;LI Fei(Department of Hematology,The First Affiliated Hospital of Nanchang University;Institute of Hematology,Academy of Clinical Medicine of Jiangxi Province;Institute of Lymphatic Tumor Diseases of Nanchang University,Nanchang 330006,Jiangxi Province,China)

机构地区：[1]南昌大学第一附属医院血液科 [2]江西省临床医学科学研究院血液病研究所 [3]南昌大学淋巴肿瘤疾病研究所,江西南昌330006

出　　处：《中国实验血液学杂志》2021年第5期1671-1675,共5页Journal of Experimental Hematology

基　　金：国家自然科学基金(81960043);江西省自然科学基金(20192ACB20030);江西省教育厅科学技术研究项目(GJJ180042)。

摘　　要：慢性淋巴细胞白血病(CLL)患者由于存在免疫功能紊乱,常发生自身免疫性血细胞减少,免疫性血小板减少症(ITP)是其中常见的合并症之一。CLL相关ITP的发病机制复杂,尚未完全阐明,目前研究主要针对体液免疫、细胞免疫及固有免疫失调等方面。近年来研究结果提示,基因组学的异常和micro RNA也参与了CLL相关ITP的发生。传统的ITP标准治疗对CLL相关ITP疗效欠佳,针对CLL原发病的化疗或单克隆抗体治疗能够纠正治疗血小板减少,新的靶向药物的出现为该病治疗提供了新的选择。本文就近年来针对CLL患者相关ITP的发病机制、预后及治疗的最新研究进展作一综述。Chronic lymphocytic leukemia(CLL)patients usually show immune dysfunction,which often leads to autoimmune hemocytopenia.Immune thrombocytopenia(ITP)is one of the common complications.The pathogenesis of CLL-related ITP is complex and has not been fully elucidated.At present,the researches mainly focus on humoral immunity,cellular immunity and innate immune disorders.Recent studies suggest that genomic abnormalities and microRNAs are also involved in CLL-related ITP.Traditional ITP standard therapy has a poor effect on CLL-related ITP.Chemotherapy or monoclonal antibody therapy against the primary pathogenesis of CLL can effectively treat thrombocytopenia,and the emergence of new targeted drugs also provides new treatment options for the disease.In this paper,the progresses of CLL-related ITP pathogenesis,prognosis and treatment in recent years are reviewed.

关 键 词：免疫性血小板减少症 慢性淋巴细胞白血病 机制 治疗 

分 类 号：R558.2[医药卫生—血液循环系统疾病]